CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review,  May  2016

 

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

 

A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model.
Flechsig P1,2, Kratochwil C3, Warth A4,2, et al. Mol Imaging Biol. 2016 Apr;18(2):243-8. doi: 10.1007/s11307-015-0890-0.

Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. Wen M1, Wang X1, Sun Y1, Xia J1, Fan L1, Xing H1, Zhang Z1, Li X1. Onco Targets Ther. 2016 Apr 5;9:1989-95. doi: 10.2147/OTT.S100303. eCollection 2016.

Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Lee JE1, Park HS1, Lee D1, et al. Biochem Biophys Res Commun. 2016 Apr 20. pii: S0006-291X(16)30595-2. doi: 10.1016/j.bbrc.2016.04.089. [Epub ahead of print]

Lentivirus-mediated knockdown of TSP50 suppresses the growth of non-small cell lung cancer cells via G0/G1 phase arrest. Qiao WL1, Hu HY1, Shi BW1, Zang LJ2, Jin W3, Lin Q1. Oncol Rep. 2016 Apr 20. doi: 10.3892/or.2016.4763. [Epub ahead of print]

Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Lee HJ1, Hanibuchi M1, Kim SJ1, et al. Neuro Oncol. 2016 Apr;18(4):486-96. doi: 10.1093/neuonc/now037.

 

SCREENING, DIAGNOSIS AND STAGING

Negative EBUS-TBNA Predicts Very Low Prevalence of Mediastinal Disease in Staging of Non-Small Cell Lung Cancer. Taverner J1, Cheang MY, Antippa P, See K, Irving LB, Steinfort DP. J Bronchology Interv Pulmonol. 2016 Apr;23(2):177-80. doi: 10.1097/LBR.0000000000000234.

The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and ‘hard-to-reach’ patients. Quaife SL1, Ruparel M2, Beeken RJ3, et al. BMC Cancer. 2016 Apr 20;16(1):281. doi: 10.1186/s12885-016-2316-z.

The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. Travis WD1, Asamura H2, Bankier AA3, et al. J Thorac Oncol. 2016 Apr 20. pii: S1556-0864(16)30335-5. doi: 10.1016/j.jtho.2016.03.025. [Epub ahead of print]

Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society. Roy-Chowdhuri S, Aisner DL, Allen TC, et al. Arch Pathol Lab Med. 2016 Apr 15. [Epub ahead of print]

Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Schneider F1, Derrick V1, Davison JM1, Strollo D2, Incharoen P1, Dacic S1. Mod Pathol. 2016 Apr 15. doi: 10.1038/modpathol.2016.66. [Epub ahead of print]

Initial Outcomes of a Lung Cancer Screening Program in an Integrated Community Health System. Miller AT1, Kruger P2, Conner K3, Robertson T4, Rowley B4, Sause W5, Ruckdeschel JC6, Blagev DP7. J Am Coll Radiol. 2016 Apr 28. pii: S1546-1440(16)00142-3. doi: 10.1016/j.jacr.2016.02.013. [Epub ahead of print]

 

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non-Small Cell Lung Cancer: A Veterans’ Affairs Central Cancer Registry (VACCR) Database Analysis.
Ganti AK1, Gonsalves W, Loberiza FR Jr, et al. Am J Clin Oncol. 2016 Apr;39(2):142-6. doi: 10.1097/COC.0000000000000040.

Chest pain control with kinesiology taping after lobectomy for lung cancer: initial results of a randomized placebo-controlled study. Imperatori A1, Grande A2, Castiglioni M3, et al. Interact Cardiovasc Thorac Surg. 2016 Apr 29. pii: ivw110. [Epub ahead of print]

Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer.
Rosen JE1, Salazar MC1, Wang Z2, et al. J Thorac Cardiovasc Surg. 2016 Apr 7. pii: S0022-5223(16)30035-6. doi: 10.1016/j.jtcvs.2016.03.060. [Epub ahead of print]

Prognostic Significance of Programmed Cell Death Ligand 1 in Patients With Non-Small-Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. Sun JM1, Zhou W2, Choi YL1, et al.

Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease undergoing lung cancer surgery: A randomised double-blinded trial.
Lee SH1, Kim N, Lee CY, Ban MG, Oh YJ. Eur J Anaesthesiol. 2016 Apr;33(4):275-82. doi: 10.1097/EJA.0000000000000405.

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
Ameratunga M1, Asadi K2, Lin X3, Walkiewicz M4, Murone C2,4, Knight S5, Mitchell P1, Boutros P3,6,7, John T1,4,8,9. PLoS One. 2016 Apr 22;11(4):e0153954. doi: 10.1371/journal.pone.0153954. eCollection 2016.

Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution. Tagawa T1, Iwata T1, Nakajima T1, Suzuki H1, Yoshida S1, Yoshino I2. World J Surg. 2016 Apr;40(4):906-12. doi: 10.1007/s00268-015-3330-z.

Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. Geissen NM1, Medairos R1, Davila E1, et al. Lung. 2016 Apr 23. [Epub ahead of print]

Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer. Kim SH1, Lee HW2, Go SI3,4, Lee SI5, Lee GW4,6. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8809. [Epub ahead of print]

Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). Kent MS1, Mandrekar SJ2, Landreneau R3, et al. Ann Thorac Surg. 2016 Apr 19. pii: S0003-4975(16)00082-5. doi: 10.1016/j.athoracsur.2016.01.069. [Epub ahead of print]

Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients? Fiorelli A1, Caronia FP2, Daddi N3, et al. Surg Today. 2016 Apr 16. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

Navigating the Challenges of Adjuvant Chemotherapy in Older Patients with Early-Stage Non-Small-Cell Lung Cancer. Poudel A1, Sinha S1, Gajra A2. Drugs Aging. 2016 Apr;33(4):223-32. doi: 10.1007/s40266-016-0350-9.

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure. Cho KM1,2, Keam B1,3, Kim TM1,3, Lee SH1,3, Kim DW1,3, Heo DS1,3. Korean J Intern Med. 2016 Apr 21. doi: 10.3904/kjim.2014.259. [Epub ahead of print]

Chemotherapy in elderly patients with nonsmall cell lung cancer. Veluswamy RR1, Levy B, Wisnivesky JP. Curr Opin Pulm Med. 2016 Apr 20. [Epub ahead of print]

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Park K1, Tan EH2, O’Byrne K3, et al. Lancet Oncol. 2016 Apr 12. pii: S1470-2045(16)30033-X. doi: 10.1016/S1470-2045(16)30033-X. [Epub ahead of print]

 

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Stereotactic Body Radiation Therapy as Salvage for Intrathoracic Recurrence in Patients With Previously Irradiated Locally Advanced Non-Small Cell Lung Cancer. Parks J1, Kloecker G, Woo S, Dunlap NE. Am J Clin Oncol. 2016 Apr;39(2):147-53. doi: 10.1097/COC.0000000000000039.

Phase II Trial of Stereotactic Body Radiotherapy for Stage I NSCLC: Survival, Local Control and Lung Function at 36 months. Navarro-Martin A1, Aso S2, Cacicedo J3, et al. J Thorac Oncol. 2016 Apr 18. pii: S1556-0864(16)30092-2. doi: 10.1016/j.jtho.2016.03.021. [Epub ahead of print]

Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial. Ren XC1, Wang QY1, Zhang R1, et al. BMC Cancer. 2016 Apr 23;16(1):288. doi: 10.1186/s12885-016-2314-1.

Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases.
Bauman G1, Yartsev S2, Roberge D3, et al. J Neurooncol. 2016 Apr 15. [Epub ahead of print]

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study. Haslett K1, Franks K2, Hanna GG3, et al. BMJ Open. 2016 Apr 15;6(4):e010457. doi: 10.1136/bmjopen-2015-010457.

Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study. Roy S1, Pathy S1, Mohanti BK1, Raina V2, Jaiswal A3, Kumar R4, Kalaivani M5. Br J Radiol. 2016 Apr 7:20150966. [Epub ahead of print]

Dose-Escalation Study of Thoracic Radiotherapy in Combination With Pemetrexed Plus Cisplatin in Japanese Patients With Locally Advanced Nonsquamous Non-Small Cell Lung Cancer: A Post Hoc Analysis of Survival and Recurrent Sites. Niho S1, Nokihara H, Nihei K, et al. Am J Clin Oncol. 2016 Apr;39(2):132-5. doi: 10.1097/COC.0000000000000030.

A comparative study of the target volume definition in radiotherapy with «Slow CT Scan» vs. 4D PET/CT Scan in early stages non-small cell lung cancer. [Article in English, Spanish]
Molla M1, Anducas N2, Simó M3, et al. Rev Esp Med Nucl Imagen Mol. 2016 Apr 19. pii: S2253-654X(16)00025-1. doi: 10.1016/j.remn.2016.02.003. [Epub ahead of print]

Hypofractionated 3D radiotherapy for inoperable T1-3 N0-1 non-small-cell lung cancer. Mollà Armadà M1, Saez J2, Ramos M1, Giraldo A1, Seoane A2, Andreu J3, Simó M4, Giralt J1. Br J Radiol. 2016 Apr 7:20150824. [Epub ahead of print]

Apparent diffusion coefficient (ADC) change on repeated diffusion-weighted magnetic resonance imaging during radiochemotherapy for non-small cell lung cancer: A pilot study. Weiss E1, Ford JC2, Olsen KM3, Karki K4, Saraiya S4, Groves R5, Hugo GD4. Lung Cancer. 2016 Jun;96:113-9. doi: 10.1016/j.lungcan.2016.04.001. Epub 2016 Apr 4.
further investigation.

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Zhou L1, He J1, Xiong W1, et al. Lung Cancer. 2016 Jun;96:93-100. doi: 10.1016/j.lungcan.2016.04.003. Epub 2016 Apr 6.

Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non-small cell lung cancer. Harada H1, Fuji H1, Ono A2, et al. Cancer Sci. 2016 Apr 25. doi: 10.1111/cas.12955. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Fiorentino FP1, Tokgün E1, Solé-Sánchez S1, et al. Oncotarget. 2016 Apr 18. doi: 10.18632/oncotarget.8826. [Epub ahead of print]

Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ1, Feng Y2, Mukherjee S1, et al. PLoS One. 2016 Apr 7;11(4):e0152584. doi: 10.1371/journal.pone.0152584. eCollection 2016.
warranting further investigation of such combinations in SCLC patients.

A phase II study of nintedanib in patients with relapsed small cell lung cancer. Han JY1, Kim HY2, Lim KY2, Hwangbo B2, Lee JS2. Lung Cancer. 2016 Jun;96:108-12. doi: 10.1016/j.lungcan.2016.04.002. Epub 2016 Apr 6.

Is the canonical RAF-MEK-ERK signaling pathway a therapeutic target in SCLC? Cristea S1, Sage J2. J Thorac Oncol. 2016 Apr 28. pii: S1556-0864(16)30383-5. doi: 10.1016/j.jtho.2016.04.018. [Epub ahead of print]

Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study. Aktas G1, Kus T1, Kalender ME1, Sevinc A1, Camci C1, Kul S2. Onco Targets Ther. 2016 Apr 1;9:1921-6. doi: 10.2147/OTT.S101390. eCollection 2016.

PALLIATIVE AND SUPPORTIVE CARE

Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Xiao X1, He Z1, Cao W2, et al. Int J Oncol. 2016 Apr 15. doi: 10.3892/ijo.2016.3488. [Epub ahead of print]

Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer. Morio K, Minami T, Sozu T, Niki K, Kijima T, Uejima E, Morio K. Chemotherapy. 2016;61(5):256-61. doi: 10.1159/000443983. Epub 2016 Apr 1.

Patterns of Palliative Care Consultation Among Elderly Patients With Cancer. Roeland EJ1, Triplett DP1, Matsuno RK1, et al. J Natl Compr Canc Netw. 2016 Apr;14(4):439-45.

Impact of self-reported physical activity and health promotion behaviors on lung cancer survivorship. Sloan JA1, Cheville AL2, Liu H3, et al. Health Qual Life Outcomes. 2016 Apr 29;14(1):66. doi: 10.1186/s12955-016-0461-3.

Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Sjøblom B1, Grønberg BH2, Wentzel-Larsen T3, et al. Clin Nutr. 2016 Apr 1. pii: S0261-5614(16)00101-1. doi: 10.1016/j.clnu.2016.03.010. [Epub ahead of print]

Using Perceived Self-efficacy to Improve Fatigue and Fatigability In Postsurgical Lung Cancer Patients: A Pilot Randomized Controlled Trial. Hoffman AJ1, Brintnall RA, Given BA, von Eye A, Jones LW, Brown JK. Cancer Nurs. 2016 Apr 29. [Epub ahead of print]

The relationship between coping strategies, quality of life, and mood in patients with incurable cancer. Nipp RD1, El-Jawahri A1, Fishbein JN2, et al. Cancer. 2016 Apr 18. doi: 10.1002/cncr.30025. [Epub ahead of print]

Cachexia among US cancer patients. Arthur ST1, Van Doren BA1, Roy D1, Noone JM1, Zacherle E1, Blanchette CM1. J Med Econ. 2016 Apr 21:1-22. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

Metastasized lung cancer suppression by Morinda citrifolia (Noni) leaf compared to Erlotinib via anti-inflammatory, endogenous antioxidant responses and apoptotic gene activation. Lim SL1, Mustapha NM2, Goh YM2, Bakar NA1, Mohamed S3. Mol Cell Biochem. 2016 Apr 22. [Epub ahead of print]

Acupuncture for Dyspnea in Lung Cancer: Results of a Feasibility Trial. Bauml J1, Haas A2, Simone CB 2nd3, Li SQ4, Cohen RB5, Langer CJ5, Mao JJ6. Integr Cancer Ther. 2016 Apr 24. pii: 1534735415624138. [Epub ahead of print]

MISCELLANEOUS WORKS

The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. Abu-Hejleh T1, Chrischilles EA, Halfdanarson TR, et al. Am J Clin Oncol. 2016 Apr;39(2):126-31. doi: 10.1097/COC.0000000000000029.

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) – associations with gene expression, mutational load and survival. Budczies J1,2, Bockmayr M1, Denkert C1,2, et al. Genes Chromosomes Cancer. 2016 Apr 22. doi: 10.1002/gcc.22365. [Epub ahead of print]

Specialty pharmacy services for patients receiving oral medications for solid tumors. Stein J1, Mann J2. Am J Health Syst Pharm. 2016 Apr 28. pii: ajhp150863. [Epub ahead of print]

 

 

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)